nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.777	1	CiPCiCtD
Sirolimus—CYP3A7—Sorafenib—thyroid cancer	0.017	0.223	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.017	0.223	CbGbCtD
Sirolimus—CYP3A5—Sorafenib—thyroid cancer	0.0127	0.167	CbGbCtD
Sirolimus—ABCB1—Sorafenib—thyroid cancer	0.00828	0.109	CbGbCtD
Sirolimus—CYP3A4—Vandetanib—thyroid cancer	0.00823	0.108	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—thyroid cancer	0.00502	0.066	CbGbCtD
Sirolimus—CYP3A4—Sorafenib—thyroid cancer	0.00496	0.0652	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—thyroid cancer	0.00301	0.0395	CbGbCtD
Sirolimus—EIF4E—head—thyroid cancer	0.000933	0.118	CbGeAlD
Sirolimus—MTOR—neck—thyroid cancer	0.000855	0.108	CbGeAlD
Sirolimus—FGF2—trachea—thyroid cancer	0.000811	0.102	CbGeAlD
Sirolimus—FKBP1A—neck—thyroid cancer	0.000769	0.0971	CbGeAlD
Sirolimus—FGF2—thyroid gland—thyroid cancer	0.000641	0.081	CbGeAlD
Sirolimus—FKBP1A—trachea—thyroid cancer	0.000463	0.0584	CbGeAlD
Sirolimus—MTOR—thyroid gland—thyroid cancer	0.000407	0.0514	CbGeAlD
Sirolimus—FGF2—lymph node—thyroid cancer	0.000398	0.0503	CbGeAlD
Sirolimus—FKBP1A—thyroid gland—thyroid cancer	0.000366	0.0462	CbGeAlD
Sirolimus—MTOR—head—thyroid cancer	0.000361	0.0456	CbGeAlD
Sirolimus—FKBP1A—head—thyroid cancer	0.000325	0.041	CbGeAlD
Sirolimus—SLC47A1—thyroid gland—thyroid cancer	0.000315	0.0397	CbGeAlD
Sirolimus—SLC47A1—head—thyroid cancer	0.000279	0.0352	CbGeAlD
Sirolimus—MTOR—lymph node—thyroid cancer	0.000253	0.0319	CbGeAlD
Sirolimus—FKBP1A—lymph node—thyroid cancer	0.000227	0.0287	CbGeAlD
Sirolimus—SLC47A1—lymph node—thyroid cancer	0.000195	0.0247	CbGeAlD
Sirolimus—ABCB1—trachea—thyroid cancer	0.000107	0.0135	CbGeAlD
Sirolimus—ABCB1—thyroid gland—thyroid cancer	8.47e-05	0.0107	CbGeAlD
Sirolimus—ABCB1—head—thyroid cancer	7.51e-05	0.00949	CbGeAlD
Sirolimus—Body temperature increased—Sorafenib—thyroid cancer	7.35e-05	0.000885	CcSEcCtD
Sirolimus—Abdominal pain—Sorafenib—thyroid cancer	7.35e-05	0.000885	CcSEcCtD
Sirolimus—Renal impairment—Epirubicin—thyroid cancer	7.35e-05	0.000885	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Epirubicin—thyroid cancer	7.22e-05	0.00087	CcSEcCtD
Sirolimus—Hepatic failure—Doxorubicin—thyroid cancer	7.2e-05	0.000867	CcSEcCtD
Sirolimus—Hypoglycaemia—Epirubicin—thyroid cancer	7.17e-05	0.000863	CcSEcCtD
Sirolimus—Cardiac failure congestive—Doxorubicin—thyroid cancer	7.13e-05	0.000859	CcSEcCtD
Sirolimus—Hyponatraemia—Epirubicin—thyroid cancer	7.02e-05	0.000845	CcSEcCtD
Sirolimus—Osteoarthritis—Epirubicin—thyroid cancer	6.99e-05	0.000842	CcSEcCtD
Sirolimus—Increased appetite—Doxorubicin—thyroid cancer	6.89e-05	0.000829	CcSEcCtD
Sirolimus—Affect lability—Epirubicin—thyroid cancer	6.88e-05	0.000829	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Doxorubicin—thyroid cancer	6.86e-05	0.000826	CcSEcCtD
Sirolimus—Hypersensitivity—Sorafenib—thyroid cancer	6.85e-05	0.000825	CcSEcCtD
Sirolimus—Renal impairment—Doxorubicin—thyroid cancer	6.8e-05	0.000819	CcSEcCtD
Sirolimus—Face oedema—Epirubicin—thyroid cancer	6.75e-05	0.000813	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Doxorubicin—thyroid cancer	6.69e-05	0.000805	CcSEcCtD
Sirolimus—Asthenia—Sorafenib—thyroid cancer	6.67e-05	0.000803	CcSEcCtD
Sirolimus—Hypoglycaemia—Doxorubicin—thyroid cancer	6.63e-05	0.000798	CcSEcCtD
Sirolimus—Mood swings—Epirubicin—thyroid cancer	6.62e-05	0.000798	CcSEcCtD
Sirolimus—Pruritus—Sorafenib—thyroid cancer	6.58e-05	0.000792	CcSEcCtD
Sirolimus—Blood creatinine increased—Epirubicin—thyroid cancer	6.55e-05	0.000789	CcSEcCtD
Sirolimus—Dehydration—Epirubicin—thyroid cancer	6.5e-05	0.000783	CcSEcCtD
Sirolimus—Hyponatraemia—Doxorubicin—thyroid cancer	6.5e-05	0.000782	CcSEcCtD
Sirolimus—Osteoarthritis—Doxorubicin—thyroid cancer	6.47e-05	0.000779	CcSEcCtD
Sirolimus—Liver function test abnormal—Epirubicin—thyroid cancer	6.46e-05	0.000777	CcSEcCtD
Sirolimus—Orthostatic hypotension—Epirubicin—thyroid cancer	6.39e-05	0.000769	CcSEcCtD
Sirolimus—Affect lability—Doxorubicin—thyroid cancer	6.37e-05	0.000767	CcSEcCtD
Sirolimus—Hypokalaemia—Epirubicin—thyroid cancer	6.36e-05	0.000766	CcSEcCtD
Sirolimus—Diarrhoea—Sorafenib—thyroid cancer	6.36e-05	0.000766	CcSEcCtD
Sirolimus—Breast disorder—Epirubicin—thyroid cancer	6.32e-05	0.000761	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	6.3e-05	0.000758	CcSEcCtD
Sirolimus—Face oedema—Doxorubicin—thyroid cancer	6.25e-05	0.000752	CcSEcCtD
Sirolimus—Gastritis—Epirubicin—thyroid cancer	6.19e-05	0.000745	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Epirubicin—thyroid cancer	6.17e-05	0.000743	CcSEcCtD
Sirolimus—Dizziness—Sorafenib—thyroid cancer	6.15e-05	0.00074	CcSEcCtD
Sirolimus—Mood swings—Doxorubicin—thyroid cancer	6.13e-05	0.000738	CcSEcCtD
Sirolimus—Abdominal distension—Epirubicin—thyroid cancer	6.08e-05	0.000733	CcSEcCtD
Sirolimus—Blood creatinine increased—Doxorubicin—thyroid cancer	6.06e-05	0.00073	CcSEcCtD
Sirolimus—Influenza—Epirubicin—thyroid cancer	6.04e-05	0.000728	CcSEcCtD
Sirolimus—Asthma—Epirubicin—thyroid cancer	6.04e-05	0.000728	CcSEcCtD
Sirolimus—Dysphagia—Epirubicin—thyroid cancer	6.04e-05	0.000728	CcSEcCtD
Sirolimus—Dehydration—Doxorubicin—thyroid cancer	6.02e-05	0.000724	CcSEcCtD
Sirolimus—Liver function test abnormal—Doxorubicin—thyroid cancer	5.97e-05	0.000719	CcSEcCtD
Sirolimus—Pancreatitis—Epirubicin—thyroid cancer	5.93e-05	0.000713	CcSEcCtD
Sirolimus—Vomiting—Sorafenib—thyroid cancer	5.91e-05	0.000712	CcSEcCtD
Sirolimus—Orthostatic hypotension—Doxorubicin—thyroid cancer	5.91e-05	0.000711	CcSEcCtD
Sirolimus—Hypokalaemia—Doxorubicin—thyroid cancer	5.89e-05	0.000709	CcSEcCtD
Sirolimus—Rash—Sorafenib—thyroid cancer	5.86e-05	0.000706	CcSEcCtD
Sirolimus—Dermatitis—Sorafenib—thyroid cancer	5.86e-05	0.000705	CcSEcCtD
Sirolimus—Breast disorder—Doxorubicin—thyroid cancer	5.85e-05	0.000704	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	5.83e-05	0.000701	CcSEcCtD
Sirolimus—Headache—Sorafenib—thyroid cancer	5.83e-05	0.000701	CcSEcCtD
Sirolimus—Bronchitis—Epirubicin—thyroid cancer	5.81e-05	0.0007	CcSEcCtD
Sirolimus—Pancytopenia—Epirubicin—thyroid cancer	5.74e-05	0.000691	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—thyroid cancer	5.73e-05	0.000689	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	5.71e-05	0.000687	CcSEcCtD
Sirolimus—Dysuria—Epirubicin—thyroid cancer	5.65e-05	0.00068	CcSEcCtD
Sirolimus—Neutropenia—Epirubicin—thyroid cancer	5.65e-05	0.00068	CcSEcCtD
Sirolimus—Abdominal distension—Doxorubicin—thyroid cancer	5.63e-05	0.000678	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Epirubicin—thyroid cancer	5.62e-05	0.000676	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—thyroid cancer	5.59e-05	0.000673	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—thyroid cancer	5.59e-05	0.000673	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—thyroid cancer	5.59e-05	0.000673	CcSEcCtD
Sirolimus—Pollakiuria—Epirubicin—thyroid cancer	5.58e-05	0.000672	CcSEcCtD
Sirolimus—Nausea—Sorafenib—thyroid cancer	5.52e-05	0.000665	CcSEcCtD
Sirolimus—Weight increased—Epirubicin—thyroid cancer	5.5e-05	0.000662	CcSEcCtD
Sirolimus—Pancreatitis—Doxorubicin—thyroid cancer	5.48e-05	0.00066	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—thyroid cancer	5.47e-05	0.000658	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—thyroid cancer	5.45e-05	0.000656	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—thyroid cancer	5.42e-05	0.000653	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—thyroid cancer	5.39e-05	0.000649	CcSEcCtD
Sirolimus—Infestation—Epirubicin—thyroid cancer	5.39e-05	0.000649	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—thyroid cancer	5.38e-05	0.000648	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—thyroid cancer	5.31e-05	0.000639	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—thyroid cancer	5.28e-05	0.000636	CcSEcCtD
Sirolimus—ABCB1—lymph node—thyroid cancer	5.26e-05	0.00664	CbGeAlD
Sirolimus—Stomatitis—Epirubicin—thyroid cancer	5.25e-05	0.000632	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—thyroid cancer	5.24e-05	0.000631	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—thyroid cancer	5.24e-05	0.000631	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—thyroid cancer	5.23e-05	0.00063	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—thyroid cancer	5.23e-05	0.00063	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—thyroid cancer	5.2e-05	0.000626	CcSEcCtD
Sirolimus—Sweating—Epirubicin—thyroid cancer	5.17e-05	0.000622	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—thyroid cancer	5.17e-05	0.000622	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—thyroid cancer	5.14e-05	0.000619	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—thyroid cancer	5.1e-05	0.000614	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—thyroid cancer	5.09e-05	0.000613	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—thyroid cancer	5.08e-05	0.000612	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—thyroid cancer	5.06e-05	0.000609	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—thyroid cancer	5.06e-05	0.000609	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—thyroid cancer	5.04e-05	0.000607	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—thyroid cancer	5.02e-05	0.000604	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—thyroid cancer	4.99e-05	0.0006	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—thyroid cancer	4.99e-05	0.0006	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—thyroid cancer	4.89e-05	0.000588	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—thyroid cancer	4.86e-05	0.000585	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—thyroid cancer	4.86e-05	0.000585	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—thyroid cancer	4.85e-05	0.000584	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—thyroid cancer	4.85e-05	0.000584	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—thyroid cancer	4.85e-05	0.000584	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—thyroid cancer	4.84e-05	0.000582	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—thyroid cancer	4.81e-05	0.00058	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—thyroid cancer	4.8e-05	0.000578	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—thyroid cancer	4.78e-05	0.000576	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—thyroid cancer	4.78e-05	0.000575	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—thyroid cancer	4.77e-05	0.000574	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—thyroid cancer	4.75e-05	0.000572	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—thyroid cancer	4.75e-05	0.000572	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—thyroid cancer	4.74e-05	0.000571	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—thyroid cancer	4.72e-05	0.000568	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—thyroid cancer	4.7e-05	0.000566	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—thyroid cancer	4.68e-05	0.000563	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—thyroid cancer	4.66e-05	0.000561	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—thyroid cancer	4.51e-05	0.000543	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—thyroid cancer	4.5e-05	0.000542	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—thyroid cancer	4.49e-05	0.000541	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—thyroid cancer	4.49e-05	0.00054	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—thyroid cancer	4.48e-05	0.000539	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—thyroid cancer	4.45e-05	0.000536	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—thyroid cancer	4.44e-05	0.000535	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—thyroid cancer	4.42e-05	0.000532	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—thyroid cancer	4.41e-05	0.000531	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—thyroid cancer	4.4e-05	0.00053	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—thyroid cancer	4.39e-05	0.000528	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—thyroid cancer	4.39e-05	0.000528	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—thyroid cancer	4.37e-05	0.000526	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—thyroid cancer	4.36e-05	0.000525	CcSEcCtD
Sirolimus—Chills—Epirubicin—thyroid cancer	4.34e-05	0.000523	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—thyroid cancer	4.31e-05	0.000519	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—thyroid cancer	4.21e-05	0.000507	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—thyroid cancer	4.17e-05	0.000502	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—thyroid cancer	4.15e-05	0.0005	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—thyroid cancer	4.15e-05	0.0005	CcSEcCtD
Sirolimus—Tension—Epirubicin—thyroid cancer	4.13e-05	0.000498	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—thyroid cancer	4.09e-05	0.000492	CcSEcCtD
Sirolimus—Back pain—Epirubicin—thyroid cancer	4.07e-05	0.00049	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—thyroid cancer	4.06e-05	0.000489	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—thyroid cancer	4.05e-05	0.000487	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—thyroid cancer	4.04e-05	0.000487	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—thyroid cancer	4.03e-05	0.000486	CcSEcCtD
Sirolimus—Chills—Doxorubicin—thyroid cancer	4.02e-05	0.000484	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—thyroid cancer	3.91e-05	0.00047	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—thyroid cancer	3.9e-05	0.000469	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—thyroid cancer	3.89e-05	0.000469	CcSEcCtD
Sirolimus—Agitation—Epirubicin—thyroid cancer	3.87e-05	0.000466	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—thyroid cancer	3.84e-05	0.000462	CcSEcCtD
Sirolimus—Tension—Doxorubicin—thyroid cancer	3.82e-05	0.00046	CcSEcCtD
Sirolimus—Malaise—Epirubicin—thyroid cancer	3.8e-05	0.000457	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—thyroid cancer	3.78e-05	0.000456	CcSEcCtD
Sirolimus—Syncope—Epirubicin—thyroid cancer	3.78e-05	0.000455	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—thyroid cancer	3.77e-05	0.000454	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—thyroid cancer	3.77e-05	0.000454	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—thyroid cancer	3.75e-05	0.000451	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—thyroid cancer	3.72e-05	0.000448	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—thyroid cancer	3.7e-05	0.000446	CcSEcCtD
Sirolimus—Cough—Epirubicin—thyroid cancer	3.67e-05	0.000442	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—thyroid cancer	3.64e-05	0.000438	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—thyroid cancer	3.62e-05	0.000435	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—thyroid cancer	3.6e-05	0.000434	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—thyroid cancer	3.59e-05	0.000432	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—thyroid cancer	3.59e-05	0.000432	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—thyroid cancer	3.59e-05	0.000432	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—thyroid cancer	3.58e-05	0.000431	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—thyroid cancer	3.57e-05	0.00043	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	3.56e-05	0.000429	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—thyroid cancer	3.54e-05	0.000426	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—thyroid cancer	3.51e-05	0.000423	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—thyroid cancer	3.49e-05	0.000421	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—thyroid cancer	3.49e-05	0.00042	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—thyroid cancer	3.47e-05	0.000417	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—thyroid cancer	3.44e-05	0.000415	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—thyroid cancer	3.44e-05	0.000414	CcSEcCtD
Sirolimus—Oedema—Epirubicin—thyroid cancer	3.44e-05	0.000414	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—thyroid cancer	3.42e-05	0.000412	CcSEcCtD
Sirolimus—Infection—Epirubicin—thyroid cancer	3.41e-05	0.000411	CcSEcCtD
Sirolimus—Cough—Doxorubicin—thyroid cancer	3.4e-05	0.000409	CcSEcCtD
Sirolimus—Shock—Epirubicin—thyroid cancer	3.38e-05	0.000407	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—thyroid cancer	3.37e-05	0.000406	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—thyroid cancer	3.37e-05	0.000405	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—thyroid cancer	3.36e-05	0.000405	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—thyroid cancer	3.35e-05	0.000404	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—thyroid cancer	3.34e-05	0.000402	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—thyroid cancer	3.32e-05	0.0004	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—thyroid cancer	3.32e-05	0.000399	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—thyroid cancer	3.32e-05	0.000399	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—thyroid cancer	3.32e-05	0.000399	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—thyroid cancer	3.31e-05	0.000398	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	3.29e-05	0.000397	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—thyroid cancer	3.28e-05	0.000395	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—thyroid cancer	3.28e-05	0.000394	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—thyroid cancer	3.21e-05	0.000387	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—thyroid cancer	3.21e-05	0.000386	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—thyroid cancer	3.18e-05	0.000383	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—thyroid cancer	3.18e-05	0.000383	CcSEcCtD
Sirolimus—Infection—Doxorubicin—thyroid cancer	3.16e-05	0.00038	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.13e-05	0.000377	CcSEcCtD
Sirolimus—Shock—Doxorubicin—thyroid cancer	3.13e-05	0.000377	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—thyroid cancer	3.12e-05	0.000375	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—thyroid cancer	3.11e-05	0.000375	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—thyroid cancer	3.11e-05	0.000374	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—thyroid cancer	3.1e-05	0.000374	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—thyroid cancer	3.09e-05	0.000372	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—thyroid cancer	3.09e-05	0.000372	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—thyroid cancer	3.07e-05	0.00037	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—thyroid cancer	3.06e-05	0.000369	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—thyroid cancer	3.06e-05	0.000368	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—thyroid cancer	3.03e-05	0.000365	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—thyroid cancer	3.03e-05	0.000364	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—thyroid cancer	2.99e-05	0.00036	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—thyroid cancer	2.97e-05	0.000358	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—thyroid cancer	2.97e-05	0.000357	CcSEcCtD
Sirolimus—Pain—Epirubicin—thyroid cancer	2.94e-05	0.000354	CcSEcCtD
Sirolimus—Constipation—Epirubicin—thyroid cancer	2.94e-05	0.000354	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	2.9e-05	0.000349	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—thyroid cancer	2.88e-05	0.000346	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—thyroid cancer	2.86e-05	0.000344	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—thyroid cancer	2.84e-05	0.000341	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—thyroid cancer	2.83e-05	0.000341	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—thyroid cancer	2.83e-05	0.00034	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—thyroid cancer	2.81e-05	0.000338	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—thyroid cancer	2.8e-05	0.000337	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—thyroid cancer	2.76e-05	0.000333	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—thyroid cancer	2.75e-05	0.000331	CcSEcCtD
Sirolimus—Pain—Doxorubicin—thyroid cancer	2.72e-05	0.000327	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—thyroid cancer	2.72e-05	0.000327	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—thyroid cancer	2.72e-05	0.000327	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—thyroid cancer	2.72e-05	0.000327	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—thyroid cancer	2.62e-05	0.000316	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—thyroid cancer	2.6e-05	0.000313	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—thyroid cancer	2.53e-05	0.000305	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—thyroid cancer	2.51e-05	0.000303	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—thyroid cancer	2.51e-05	0.000303	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—thyroid cancer	2.47e-05	0.000297	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—thyroid cancer	2.43e-05	0.000293	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—thyroid cancer	2.35e-05	0.000283	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—thyroid cancer	2.34e-05	0.000282	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—thyroid cancer	2.28e-05	0.000275	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—thyroid cancer	2.27e-05	0.000274	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—thyroid cancer	2.25e-05	0.000271	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—thyroid cancer	2.19e-05	0.000263	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—thyroid cancer	2.18e-05	0.000262	CcSEcCtD
Sirolimus—Rash—Epirubicin—thyroid cancer	2.17e-05	0.000261	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—thyroid cancer	2.17e-05	0.000261	CcSEcCtD
Sirolimus—Headache—Epirubicin—thyroid cancer	2.15e-05	0.000259	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—thyroid cancer	2.1e-05	0.000253	CcSEcCtD
Sirolimus—Nausea—Epirubicin—thyroid cancer	2.04e-05	0.000246	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—thyroid cancer	2.02e-05	0.000243	CcSEcCtD
Sirolimus—Rash—Doxorubicin—thyroid cancer	2.01e-05	0.000241	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—thyroid cancer	2e-05	0.000241	CcSEcCtD
Sirolimus—Headache—Doxorubicin—thyroid cancer	1.99e-05	0.00024	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—thyroid cancer	1.89e-05	0.000227	CcSEcCtD
Sirolimus—FGF2—Immune System—IFNA2—thyroid cancer	1.82e-05	0.000325	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSHR—thyroid cancer	1.8e-05	0.000322	CbGpPWpGaD
Sirolimus—MTOR—Disease—MEN1—thyroid cancer	1.8e-05	0.000321	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—AKT1—thyroid cancer	1.79e-05	0.00032	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CALCA—thyroid cancer	1.78e-05	0.000318	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PRKAR1A—thyroid cancer	1.77e-05	0.000317	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KRAS—thyroid cancer	1.77e-05	0.000317	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRG1—thyroid cancer	1.76e-05	0.000315	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—thyroid cancer	1.76e-05	0.000315	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KRAS—thyroid cancer	1.76e-05	0.000314	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—thyroid cancer	1.75e-05	0.000314	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—thyroid cancer	1.74e-05	0.000312	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	1.74e-05	0.000312	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDK1—thyroid cancer	1.74e-05	0.000312	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—thyroid cancer	1.74e-05	0.000311	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—thyroid cancer	1.73e-05	0.000309	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—AKT1—thyroid cancer	1.72e-05	0.000308	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.71e-05	0.000306	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	1.7e-05	0.000305	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—PTEN—thyroid cancer	1.7e-05	0.000304	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MEN1—thyroid cancer	1.69e-05	0.000303	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	1.69e-05	0.000303	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—AKT1—thyroid cancer	1.69e-05	0.000303	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TERT—thyroid cancer	1.66e-05	0.000297	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	1.65e-05	0.000295	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	1.63e-05	0.000292	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—thyroid cancer	1.63e-05	0.000291	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—thyroid cancer	1.63e-05	0.000291	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	1.63e-05	0.000291	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—AKT1—thyroid cancer	1.62e-05	0.00029	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDK1—thyroid cancer	1.61e-05	0.000288	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—thyroid cancer	1.61e-05	0.000288	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	1.6e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—thyroid cancer	1.59e-05	0.000284	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HPGD—thyroid cancer	1.59e-05	0.000284	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HIF1A—thyroid cancer	1.59e-05	0.000284	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TERT—thyroid cancer	1.58e-05	0.000283	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.58e-05	0.000283	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.56e-05	0.000279	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—AKT1—thyroid cancer	1.56e-05	0.000278	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—AKT1—thyroid cancer	1.55e-05	0.000277	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—AKT1—thyroid cancer	1.54e-05	0.000276	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	1.54e-05	0.000276	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—AKT1—thyroid cancer	1.53e-05	0.000274	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTCH1—thyroid cancer	1.53e-05	0.000274	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—AKT1—thyroid cancer	1.53e-05	0.000273	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRG1—thyroid cancer	1.52e-05	0.000271	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HIF1A—thyroid cancer	1.51e-05	0.000271	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—thyroid cancer	1.51e-05	0.000271	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—thyroid cancer	1.5e-05	0.000269	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	1.5e-05	0.000269	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—thyroid cancer	1.49e-05	0.000267	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CHST14—thyroid cancer	1.49e-05	0.000266	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.47e-05	0.000263	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.47e-05	0.000263	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.45e-05	0.000259	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	1.44e-05	0.000258	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—AKT1—thyroid cancer	1.44e-05	0.000257	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—AKT1—thyroid cancer	1.44e-05	0.000257	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	1.44e-05	0.000257	CbGpPWpGaD
Sirolimus—MTOR—Disease—CALCA—thyroid cancer	1.43e-05	0.000256	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—AKT1—thyroid cancer	1.42e-05	0.000254	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	1.41e-05	0.000252	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—AKT1—thyroid cancer	1.4e-05	0.000251	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDK1—thyroid cancer	1.4e-05	0.000251	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SST—thyroid cancer	1.4e-05	0.000251	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRG1—thyroid cancer	1.4e-05	0.00025	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TPR—thyroid cancer	1.38e-05	0.000246	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PTEN—thyroid cancer	1.37e-05	0.000244	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.36e-05	0.000243	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	1.35e-05	0.000242	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CALCA—thyroid cancer	1.35e-05	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNA2—thyroid cancer	1.35e-05	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSHR—thyroid cancer	1.34e-05	0.000239	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—AKT1—thyroid cancer	1.33e-05	0.000238	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—AKT1—thyroid cancer	1.32e-05	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—thyroid cancer	1.32e-05	0.000236	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRKAR1A—thyroid cancer	1.32e-05	0.000235	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—BRAF—thyroid cancer	1.31e-05	0.000235	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PTEN—thyroid cancer	1.3e-05	0.000233	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—thyroid cancer	1.3e-05	0.000233	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDK1—thyroid cancer	1.29e-05	0.000232	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRG1—thyroid cancer	1.29e-05	0.000231	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.27e-05	0.000227	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TPR—thyroid cancer	1.26e-05	0.000226	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MEN1—thyroid cancer	1.26e-05	0.000225	CbGpPWpGaD
Sirolimus—FGF2—Disease—TERT—thyroid cancer	1.26e-05	0.000225	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—BRAF—thyroid cancer	1.25e-05	0.000224	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PTEN—thyroid cancer	1.25e-05	0.000224	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	1.24e-05	0.000222	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—thyroid cancer	1.23e-05	0.000221	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.23e-05	0.000219	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDK1—thyroid cancer	1.22e-05	0.000218	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—thyroid cancer	1.22e-05	0.000218	CbGpPWpGaD
Sirolimus—FGF2—Disease—HIF1A—thyroid cancer	1.2e-05	0.000215	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HPGD—thyroid cancer	1.2e-05	0.000214	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—thyroid cancer	1.16e-05	0.000208	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TERT—thyroid cancer	1.16e-05	0.000208	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.16e-05	0.000207	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.15e-05	0.000205	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTCH1—thyroid cancer	1.14e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—thyroid cancer	1.13e-05	0.000203	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRG1—thyroid cancer	1.13e-05	0.000201	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—thyroid cancer	1.12e-05	0.0002	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HIF1A—thyroid cancer	1.11e-05	0.000199	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—thyroid cancer	1.11e-05	0.000198	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.1e-05	0.000197	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—thyroid cancer	1.06e-05	0.00019	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—thyroid cancer	1.05e-05	0.000188	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.05e-05	0.000187	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SST—thyroid cancer	1.04e-05	0.000186	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRG1—thyroid cancer	1.04e-05	0.000186	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	1.03e-05	0.000184	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.01e-05	0.00018	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—thyroid cancer	1e-05	0.000179	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CALCA—thyroid cancer	1e-05	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Disease—BRAF—thyroid cancer	9.95e-06	0.000178	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRG1—thyroid cancer	9.8e-06	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—thyroid cancer	9.78e-06	0.000175	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NDUFA13—thyroid cancer	9.75e-06	0.000174	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PTEN—thyroid cancer	9.68e-06	0.000173	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.65e-06	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—thyroid cancer	9.64e-06	0.000172	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—thyroid cancer	9.62e-06	0.000172	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC5A5—thyroid cancer	9.45e-06	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Disease—TERT—thyroid cancer	9.33e-06	0.000167	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTEN—thyroid cancer	9.29e-06	0.000166	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTEN—thyroid cancer	9.25e-06	0.000166	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.25e-06	0.000165	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—thyroid cancer	9.2e-06	0.000165	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CHST14—thyroid cancer	9.16e-06	0.000164	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—thyroid cancer	9.15e-06	0.000164	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TPR—thyroid cancer	9.13e-06	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDK1—thyroid cancer	9.06e-06	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	8.98e-06	0.000161	CbGpPWpGaD
Sirolimus—MTOR—Disease—HIF1A—thyroid cancer	8.92e-06	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—thyroid cancer	8.92e-06	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTEN—thyroid cancer	8.83e-06	0.000158	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TERT—thyroid cancer	8.8e-06	0.000157	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—RXRA—thyroid cancer	8.65e-06	0.000155	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—thyroid cancer	8.63e-06	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—thyroid cancer	8.51e-06	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—thyroid cancer	8.51e-06	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HIF1A—thyroid cancer	8.42e-06	0.000151	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.42e-06	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—thyroid cancer	8.29e-06	0.000148	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—thyroid cancer	8.25e-06	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—thyroid cancer	8.17e-06	0.000146	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—thyroid cancer	8.04e-06	0.000144	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—RXRA—thyroid cancer	7.94e-06	0.000142	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—thyroid cancer	7.88e-06	0.000141	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—thyroid cancer	7.87e-06	0.000141	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—thyroid cancer	7.83e-06	0.00014	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	7.75e-06	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—thyroid cancer	7.59e-06	0.000136	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—thyroid cancer	7.52e-06	0.000134	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—thyroid cancer	7.43e-06	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—thyroid cancer	7.39e-06	0.000132	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPGD—thyroid cancer	7.39e-06	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRG1—thyroid cancer	7.28e-06	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—thyroid cancer	7.22e-06	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—thyroid cancer	7.14e-06	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—thyroid cancer	7.1e-06	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—thyroid cancer	7.01e-06	0.000125	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—thyroid cancer	6.97e-06	0.000125	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TPR—thyroid cancer	6.89e-06	0.000123	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.89e-06	0.000123	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC5A5—thyroid cancer	6.83e-06	0.000122	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—thyroid cancer	6.78e-06	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—thyroid cancer	6.78e-06	0.000121	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PRKAR1A—thyroid cancer	6.78e-06	0.000121	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—thyroid cancer	6.71e-06	0.00012	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—thyroid cancer	6.53e-06	0.000117	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—thyroid cancer	6.48e-06	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—thyroid cancer	6.32e-06	0.000113	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—thyroid cancer	6.26e-06	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—thyroid cancer	6.25e-06	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—thyroid cancer	6.07e-06	0.000108	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—thyroid cancer	6.04e-06	0.000108	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—thyroid cancer	6.03e-06	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—thyroid cancer	5.97e-06	0.000107	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—thyroid cancer	5.83e-06	0.000104	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.81e-06	0.000104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—thyroid cancer	5.78e-06	0.000103	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—thyroid cancer	5.77e-06	0.000103	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RXRA—thyroid cancer	5.74e-06	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—thyroid cancer	5.64e-06	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—thyroid cancer	5.58e-06	9.98e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—thyroid cancer	5.46e-06	9.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—thyroid cancer	5.38e-06	9.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—thyroid cancer	5.36e-06	9.58e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—thyroid cancer	5.33e-06	9.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—thyroid cancer	5.2e-06	9.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—thyroid cancer	5.17e-06	9.25e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC5A5—thyroid cancer	5.16e-06	9.22e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—thyroid cancer	5.09e-06	9.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—thyroid cancer	5.09e-06	9.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—thyroid cancer	5.03e-06	9e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—thyroid cancer	5.01e-06	8.97e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—thyroid cancer	4.98e-06	8.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—thyroid cancer	4.96e-06	8.87e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—thyroid cancer	4.91e-06	8.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—thyroid cancer	4.64e-06	8.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—thyroid cancer	4.58e-06	8.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—thyroid cancer	4.42e-06	7.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—thyroid cancer	4.38e-06	7.84e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—thyroid cancer	4.38e-06	7.83e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RXRA—thyroid cancer	4.33e-06	7.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—thyroid cancer	4.33e-06	7.74e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—thyroid cancer	4.3e-06	7.69e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TPR—thyroid cancer	4.24e-06	7.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—thyroid cancer	4.23e-06	7.57e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.17e-06	7.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—thyroid cancer	4.04e-06	7.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—thyroid cancer	4e-06	7.15e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—thyroid cancer	3.94e-06	7.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—thyroid cancer	3.78e-06	6.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—thyroid cancer	3.77e-06	6.75e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—thyroid cancer	3.75e-06	6.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—thyroid cancer	3.73e-06	6.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—thyroid cancer	3.68e-06	6.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—thyroid cancer	3.64e-06	6.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—thyroid cancer	3.62e-06	6.48e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—thyroid cancer	3.44e-06	6.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—thyroid cancer	3.4e-06	6.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—thyroid cancer	3.35e-06	5.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—thyroid cancer	3.25e-06	5.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—thyroid cancer	3.25e-06	5.81e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—thyroid cancer	3.21e-06	5.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.18e-06	5.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—thyroid cancer	3e-06	5.36e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—thyroid cancer	2.85e-06	5.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—thyroid cancer	2.83e-06	5.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—thyroid cancer	2.8e-06	5.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—thyroid cancer	2.73e-06	4.89e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RXRA—thyroid cancer	2.67e-06	4.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—thyroid cancer	2.49e-06	4.45e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—thyroid cancer	2.49e-06	4.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—thyroid cancer	2.38e-06	4.25e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—thyroid cancer	2.16e-06	3.86e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—thyroid cancer	2.15e-06	3.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—thyroid cancer	2.1e-06	3.76e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—thyroid cancer	1.98e-06	3.55e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—thyroid cancer	1.88e-06	3.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—thyroid cancer	1.68e-06	3.01e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—thyroid cancer	1.43e-06	2.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.33e-06	2.37e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—thyroid cancer	1.16e-06	2.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—thyroid cancer	1.08e-06	1.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—thyroid cancer	6.66e-07	1.19e-05	CbGpPWpGaD
